The problem this solves is to shine a light on the inverse price wars going on in drug pricing. List prices increase dramatically while rebates are offers to lower the net price. Pharmacy benefits managers who do the negotiation like this because they earn money on the rebates(which are also shared with insurance companies) and insurance likes this because copay is a fixed rate on list price and not net price. And both of these actors who cooperate to increase list prices get to blame the increases on drug producers who year after year earn less per sold product because of the rebates.

This will however not solve anything only make it visible. Copay should be changed to work on net price after rebates, and some serius investigation of the middlemen needs to be instigated.